Quantcast

Latest Mylan Stories

2014-08-25 08:28:25

SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Thesan Pharmaceuticals announced today the appointment of Bhaskar Chaudhuri Ph.D., to its Board of Directors. Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming...

2014-08-22 08:24:49

PITTSBURGH, Aug. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic...

2014-08-18 12:27:41

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "The Overveiw of Japanese Generic Drug Market" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 This report talks about the overview of Japanese generic drug market. It gives the readers ann understanding of the overall climate surrounding generic market in Japan. The report covers related regulations, generics's share in Japan, market size, primary makers, market trend,...

2014-08-11 08:28:44

PITTSBURGH, Aug. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.(1) CEO...

2014-08-07 12:28:30

DUBLIN, Aug. 7, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Transdermal Drug Delivery Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal...

2014-08-05 04:21:28

EATONTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") has signed an Exclusive Development, Supply & Distribution Agreement with Dexcel Ltd. ("Dexcel") for an Extended Release ANDA drug product. Dexcel will be responsible for the development, registration and manufacturing of the product, and Heritage Pharmaceuticals will be responsible for marketing and distribution in the U.S. The product generates generic annual U.S. sales of approximately $60...

2014-07-23 08:30:32

District Court Judge Orders Apotex to Immediately Recall the Authorized Generic from its Direct Customers and to Stop Selling and Supplying the Product PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil(®)...

2014-07-17 08:28:43

PITTSBURGH, July 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK) in relation to Paroxetine CR, the generic version of GSK's Paxil(®) CR. GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106,700,000 by the District...

2014-07-17 04:20:56

GENEVA, July 17, 2014 /PRNewswire/ -- MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure Three days before the start of the 20th International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool (MPP) announced seven new sub-licensing agreements for the manufacture of generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG). The...

2014-07-14 08:25:52

Abbott will retain its branded generics pharmaceuticals business in emerging markets ABBOTT PARK, Ill., July 14, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. This represents a value of approximately...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related